Evaluating Candidate Principal Surrogate Endpoints

DOI10.1111/J.1541-0420.2008.01014.XzbMATH Open1152.62389OpenAlexW4300780642WikidataQ43070037 ScholiaQ43070037MaRDI QIDQ3549407FDOQ3549407

Authors: Peter B. Gilbert, Michael G. Hudgens 

Publication date: 22 December 2008

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc2726718

Recommendations

• The Evaluation of Multiple Surrogate Endpoints
• The evaluation of surrogate endpoints.
• Comparing biomarkers as principal surrogate endpoints
• Criteria for Surrogate End Points
• Principal causal effect identification and surrogate end point evaluation by multiple trials
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• Criteria for Surrogate end Points Based on Causal Distributions
• Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption

zbMATH Keywords

causal inferenceprincipal stratificationclinical trialstructural modelPrentice criteriaHIV vaccinecase cohortpostrandomization selection bias

Mathematics Subject Classification ID

Estimation in survival analysis and censored data (62N02) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Cites Work

• Principal stratification in causal inference
• An analytic method for randomized trials with informative censoring. I
• A case-cohort design for epidemiologic cohort studies and disease prevention trials
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• Evaluating the Predictiveness of a Continuous Marker
• Augmented Designs to Assess Immune Response in Vaccine Trials

Cited In (47)

• Principal stratification in causal inference
• Causal inference: a missing data perspective
• Design and estimation for evaluating principal surrogate markers in vaccine trials
• An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference
• Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
• Robust methods to correct for measurement error when evaluating a surrogate marker
• On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints
• Quantifying the feasibility of shortening clinical trial duration using surrogate markers
• A causal framework for surrogate endpoints with semi-competing risks data
• Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model
• Solutions for Surrogacy Validation with Longitudinal Outcomes for a Gene Therapy
• Surrogate measures and consistent surrogates
• Evaluation of longitudinal surrogate markers
• Discussion on ``Surrogate measures and consistent surrogates
• Discussion on ``Surrogate measures and consistent surrogates
• Rejoinder on: ``Surrogate measures and consistent surrogates
• Comparing biomarkers as principal surrogate endpoints
• Assessing heterogeneity in surrogacy using censored data
• Flexible evaluation of surrogate markers with Bayesian model averaging
• A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
• Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm
• Using principal stratification in analysis of clinical trials
• Using a surrogate with heterogeneous utility to test for a treatment effect
• Causal measures of the treatment effect captured by candidate surrogate endpoints
• Surrogacy validation for time-to-event outcomes with illness-death frailty models
• Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials
• Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials
• Exploiting multiple outcomes in Bayesian principal stratification analysis with application to the evaluation of a job training program
• Bayesian methods for multiple mediators: relating principal stratification and causal mediation in the analysis of power plant emission controls
• Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
• Testing for Heterogeneity in the Utility of a Surrogate Marker
• Estimation of the proportion of treatment effect explained by a high-dimensional surrogate
• An information-theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: application to vaccine evaluation
• Using Secondary Outcomes to Sharpen Inference in Randomized Experiments With Noncompliance
• A multiple imputation approach for the evaluation of surrogate markers in the principal stratification causal inference framework
• Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
• Augmented designs to assess principal strata direct effects
• A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint
• The Evaluation of Multiple Surrogate Endpoints
• Principal causal effect identification and surrogate end point evaluation by multiple trials
• Assessing vaccine effects in repeated low-dose challenge experiments
• Identification of causal effects within principal strata using auxiliary variables
• Identification and estimation of causal effects in the presence of confounded principal strata
• Assessing the value of a censored surrogate outcome
• Comparing biomarkers as trial level general surrogates
• Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
• A unified evaluation of differential vaccine efficacy

This page was built for publication: Evaluating Candidate Principal Surrogate Endpoints

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3549407)